MiR-200c与脏器纤维化的研究进展  

Recent advances in miR-200c and fibrosis in organs

作　　者：陈珺[1] 蔡晋宇 杜翠[1] 曹琼[1] 李敏[1] 刘斌杰[1] 

机构地区：[1]中南大学湘雅口腔医院牙周科,长沙410078

出　　处：《中南大学学报（医学版）》2017年第2期226-232,共7页Journal of Central South University ：Medical Science

摘　　要：MiR-200c在肺、肝、肾、腹膜、皮肤纤维化及翼状胬肉中异常表达。多项研究表明miR-200c与脏器纤维化密切相关,miR-200c主要通过调控TGF-β介导的上皮间质转化参与调控纤维化的发生发展;血清中miR-200c的表达异常可能为肺纤维化的早期诊断提供依据,实验表明miRNA mimics,miRNA agomir,miRNA抑制剂是纤维化潜在的靶标治疗工具。作者对miR-200c的表达、调控及其在脏器纤维化的诊断、治疗和预后判断中的作用进行了综述。In the fibrosis and pterygium of lung, liver, kidney, peritoneum or skin, miR-200c was aberrantly expressed. It has been shown that the regulatory effect of miR-200c on fibrosis in organ was involved in TGF-β-mediated epithelial-mesenchymal transition. The abnormal level of miR-200c in serum may be a basis for early diagnosis of lung fibrosis. Furthermore, miRNA mimics, miRNA agomir, and miRNA inhibitor are potential therapeutic tools for fibrosis. In present review, we summarize the recent progress in relevant studies on the expression and regulatory function ofmiR- 200c and focus on its role in diagnosis, treatment, and prognosis of fibrosis in organ.

关 键 词：MIR-200C 纤维化 靶基因 

分 类 号：R363[医药卫生—病理学]